Clinical trials: Schizotypal Personality Disorder
Prodromal Schizophrenia, Psychosis
Feasibility Trial of a Lifestyle Intervention for CHR-P
The present study will assess the feasibility and social validity of an adjunctive health promotion group for youth and clinical high risk for psychosis (CHR-P).
- Conditions
- Prodromal Schizophrenia, Psychosis, Psychological Disorder, Psychological Stress
- Trial name
- NCT05532683
- Testing
- Health Behaviors Group
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of California, Los Angeles
Prodromal Schizophrenia
Effects of Cognitive Remediation on Cognition in Young People at Clinical High Risk of Psychosis
Onset of psychotic disorders such as schizophrenia, typically occurs during late adolescence or early adulthood often resulting in chronic social and occupational disability.
- Trial name
- NCT01619319
- Testing
- Cognitive Remediation Therapy, computer games
- Volunteers
- 32 people
- Sponsor
- University of Calgary
Prodromal Schizophrenia
Evaluation of Step-Based Care for Individuals at Clinical High Risk for Psychosis
The Ohio State University Early Psychosis Intervention Center is implementing a specialized clinical program to serve individuals who meet clinical high risk criteria for a psychosis.
- Trial name
- NCT03970005
- Testing
- Step-Based Care Model
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Ohio State University
Schizophrenia, Schizotypal Disorder
The OPUS YOUNG Trial. Early Intervention Versus Treatment as Usual for Adolescents With First-episode Psychosis
The OPUS YOUNG (OY) study investigates the efficacy of early intervention service versus treatment as usual (TAU) for adolescents aged 12-17 years with a first-episode psychosis.
- Conditions
- Schizophrenia, Schizotypal Disorder, Delusional Disorder, Acute and Transient Psychotic Disorder, Unspecified
- Trial name
- OPUS-YOUNG (NCT04916626)
- Testing
- OPUS YOUNG, Treatment as Usual
- Where
- Denmark
- Volunteers
- 284 people
- Sponsor
- Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Prodromal Schizophrenia
Effects of NAC on Symptoms of CHR Patients
Schizophrenia is a chronic debilitating psychotic disorder. Identifying persons with "clinical high-risk" (CHR) symptoms, which are like those of schizophrenia but less severe, and providing psychiatric care to these individuals…
- Trial name
- NCT05142735
- Testing
- N-Acetylcysteine
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- Centre for Addiction and Mental Health
Psychotic Disorders, Psychosis
Semantic and Syntactic Computerized Analysis of Free Speech
Subtle speech disorganization could be predictive of a transition to schizophrenia of ultra-high-risk patients. The aim of our longitudinal multicenter cohort study is to identify specific linguistic markers of the psychotic…
- Conditions
- Psychotic Disorders, Psychosis, Schizophrenia and Related Disorders, Schizophrenia Prodromal
- Trial name
- ASESID (NCT03525054)
- Where
- 3 sites in France
- Volunteers
- 215 people
- Sponsor
- University Hospital, Brest
Prodromal Schizophrenia, Prodromal Psychosis
Aripiprazole Treatment of the Prodrome
The RAP Program is conducting a research study of the antipsychotic medication Aripiprazole. This drug has been approved for treating symptoms associated with schizophrenia and is associated with fewer side effects.
- Trial name
- NCT00169949
- Testing
- aripiprazole
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Northwell Health
Prodromal Schizophrenia, Psychotic Disorders
Psychosis: Early Detection, Intervention and Prevention
The primary aim of this application is to conduct a randomized, controlled clinical trial of a specialized mental health service delivery system specifically developed for prodromal psychotic disorders.
- Conditions
- Prodromal Schizophrenia, Psychotic Disorders, Severe Bipolar Disorder With Psychotic Features, Severe Major Depression With Psychotic Features
- Trial name
- EDIP (NCT01597141)
- Testing
- Family-aided Assertive Community Treatment, Enhanced standard treatment
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- MaineHealth
Schizophrenia, Schizoaffective Disorder
Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
The purpose of this study is to get a better understanding of the side effect burden and identify predictors of psychotic, mood and aggressive disorders in children and adolescents.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder, Not Otherwise Specified
- Trial name
- SATIETY (NCT01269710)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of North Carolina, Chapel Hill
Psychosis, Prodromal Schizophrenia
Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis Risk
This 10 week intervention, Specific Cognitive Remediation with Surround (or SCORES), is designed to target processing speed, a cognitive domain related directly to social functioning, which in turn, represents a vulnerability…
- Conditions
- Psychosis, Prodromal Schizophrenia, Prodromal Symptoms
- Trial name
- SCORES (NCT05131035)
- Testing
- SCORES (Specific COgnitive Remediation with Support)
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Northwell Health
Prodromal Schizophrenia
Neurofeedback Training for High Risk Psychosis
Young people who are at great risk for developing psychosis have cognitive deficits which are strongly related to functioning in the community.
- Trial name
- NCT03447548
- Testing
- Neurofeedback processing speed training, Active control
- Where
- 2 sites in United States
- Volunteers
- 81 people
- Sponsor
- Hartford Hospital
Psychosis, Psychosis Nos/Other
EPI-MINN: Targeting Cognition and Motivation - National
The purpose of this study is to perform a practice-based research project designed to assess whether cognition and motivated behavior in early psychosis can be addressed as key treatment goals within real-world settings by using…
- Conditions
- Psychosis, Psychosis Nos/Other, Schizophrenia, Schizo Affective Disorder
- Trial name
- NCT05877716
- Testing
- Cognitive and Social Cognitive Training, Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App, Early Psychosis Coordinated Specialty Care
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Minnesota
Prodromal Schizophrenia
Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer
Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms of patients with schizophrenia. Whether treatment of an NMDA-enhancing agent can benefit the treatment of prodromal schizophrenia…
- Trial name
- NCT05052853
- Testing
- NMDAE
- Where
- Taiwan
- Volunteers
- 48 people
- Sponsor
- China Medical University Hospital
Psychotic Disorders, Prodromal Symptoms
Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial
The present study is a confirmatory efficacy trial of Family Focused Therapy for youth at clinical high risk for psychosis (FFT-CHR).
- Conditions
- Psychotic Disorders, Prodromal Symptoms, Prodromal Schizophrenia, Psychosis
- Trial name
- NCT04338152
- Testing
- Family Focused Therapy for Clinical High Risk Youth (FFT-CHR), Enhanced Care (EC)
- Where
- 7 sites in United States, Canada
- Volunteers
- 220 people
- Sponsor
- University of California, Los Angeles
Prodromal Schizophrenia, Psychotic Disorders
Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms
The Recognition and Prevention (RAP) Program is conducting a research study comparing an antidepressant, sertraline, alone versus in combination with a second-generation antipsychotic, risperidone, to evaluate their ability to…
- Trial name
- NCT00169988
- Testing
- risperidone, sertraline-primary
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Northwell Health
Schizophrenia Prodromal, Schizophrenia, Childhood
Patientheque in Patients With a Psychosis
Establishment of a patient library for patients who have had a first psychotic episode and who have an "at risk" status for psychotic disorder (GRD, APS, BLIPS group) or a psychosis threshold during CAARMS administration.
- Conditions
- Schizophrenia Prodromal, Schizophrenia, Childhood, Schizophrenia
- Trial name
- LONGIPEP (NCT05340348)
- Testing
- Blood samples (36 mL) + fecal samples + hair sample
- Where
- France
- Volunteers
- 250 people
- Sponsor
- University Hospital, Brest